Patent 4472301 Issued on September 18, 1984. Estimated Expiration Date: May 27, 2002. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
530/363, Serum albumin, e.g., BSA, HSA, etc.435/7.7, Assay in which a label present is an apoenzyme, prosthetic group, or enzyme cofactor435/7.71, Assay in which a label present is an enzyme inhibitor or functions to alter enzyme activity435/7.72, Assay in which a label present is an enzyme substrate or substrate analogue435/7.9, Assay in which an enzyme present is a label530/345, Chemical aftertreatment, e.g., acylation, methylation, etc.530/389.8, Binds drug, hapten, hapten-carrier complex, or specifically-identified chemical structure (e.g., theophylline, digoxin, etc.)530/404, Sulfur containing reactant530/405, Nitrogen containing reactant530/806, ANTIGENIC PEPTIDES OR PROTEINS530/809Fused cells, e.g., hybridoma, etc.
A propranolol immunogen comprising an unsubstituted hydroxypropylamine precursor of propranolol coupled through a bis-imidate linking group to an immunogenic carrier material. The immunogen is useful to stimulate the production of antibodies which recognize propranolol and can perform as reagents in immunoassays to determine propranolol.
May 27, 2002. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
